The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving ...

Number 5: The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in ...

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug ...

The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving visual acuity in patients with diabetic macular edema (DME), with comparable ...